Hunt Nimrata

EVP Hunt Nimrata sold 1,758 IDXX shares at $634.57 (now $618.92); 4 of 4 prior same-ticker sales showed 90d declines.

Hunt Nimrata sold 1,758 shares of IDEXX on 2026-03-03 at $634.57, reducing her holdings by 8.8% to 18,140 shares. The stock has since declined to $618.92 (−19.3% from the 52-week high). Notably, her prior same-ticker trade history shows a strong timing pattern: all 4 measurable prior sales at IDXX were well-timed at the 90-day mark, with negative returns ranging from −8.4% to −8.8% after the sale dates. The current transaction aligns with this historical pattern—the stock has already moved −2.2% in the 30 days following the sale. IDEXX trades at a P/E of 41.10 with recent quarterly net income of $274,610,000.00, so investors should monitor whether this latest sale precedes further weakness consistent with her past execution.

EVP Hunt Nimrata sold 2,693 IDXX shares at $661.54; 4 of 5 prior IDXX sales were well-timed.

Hunt Nimrata sold 2,693 shares (11.9% of pre-transaction holdings) at $661.54, leaving her with 19,898 shares at IDEXX LABORATORIES INC. Against her same-ticker history at IDXX, this sale extends a pattern of well-timed selling: 4 of 5 prior trades at this ticker captured declines, with 90-day returns of -8.8%, -8.4%, -8.6%, and -8.7% following those sales. The stock is now trading at $656.73, down -14.3% from its 52-week high of $766.68, suggesting the recent price pressure aligns with her historical timing edge at this specific ticker. Her broader cross-ticker track record shows a 50% well-timed rate on sells with average 90-day returns of +2.1%, but her IDXX-specific execution has been notably sharper—4 of 5 prior same-ticker sales preceded material declines rather than gains. The company remains fundamentally solid with $1.1B in quarterly revenue and 10.4% annual growth, but the cumulative selling pattern and recent 90-day decline of -12.8% merit observation.

EVP Hunt Nimrata sells 9,425 shares (30.8% reduction) for $6,629,013.52 at IDXX on 2025-11-07

Hunt Nimrata, Executive Vice President, executed 4 separate sales totaling 9,425 shares for $6,629,013.52 on 2025-11-07, reducing her holdings from 30,573 to 21,148 shares (a 30.8% reduction). The blended average price of $703.34 is near the 52-week high of $722.94 (approximately 2.7% below peak), executed during a strong uptrend where the stock has advanced 15.2% in 30 days and 8.8% in 90 days. Her prior same-ticker sales at IDXX in August 2025 showed mixed timing outcomes, with 0 of 4 prior sells proving well-timed at the 90-day mark; August sales subsequently posted positive returns of +7.9% to +14.6%, suggesting she sold before stock appreciation. The current holding of 21,148 shares demonstrates substantial ongoing ownership, which constrains any inference of fundamental concern while still representing a material reduction in her concentrated position.

EVP Hunt Nimrata sold 1,200 shares of IDXX at $656.53 on 2025-08-11, reducing holdings by 6.2% to 18,032 shares.

Hunt Nimrata, EVP, sold 1,200 shares for $787,840.20, reducing her holdings from 19,232 to 18,032 shares. This sale occurred as the stock was up 24.9% over 30 days and 29.7% over 90 days, trading at $663.92 currently versus a 52-week high of $682.78. The company's fundamentals show stable quarterly revenue of $1,109,457,000 with net income of $293,989,000, though the elevated P/E of 53.89 reflects market expectations. Notably, the insider executed three separate sales on 2025-08-06 (outcomes not yet measurable), followed by this transaction five days later, suggesting a structured approach to position reduction rather than a reactive market timing decision.

EVP Hunt Nimrata sells 7,143 shares of IDXX for $4,503,163.48 in 3 transactions; retains 18,006 shares.

Hunt Nimrata, Executive Vice President at IDEXX Laboratories, executed 3 separate sales totaling 7,143 shares for $4,503,163.48 on 2025-08-06, with a blended average price of $630.43. The sale reduces her holdings from 25,149 shares to 18,006 shares, representing a 28.4% reduction in position size. IDXX trades at $658.06 currently, 3.6% below its 52-week high of $682.78 and up 21.7% over the past 30 days and 33.8% over 90 days, suggesting the stock has appreciated meaningfully in the recent period. The filing provides no information regarding whether this sale was scheduled under a 10b5-1 plan or discretionary, leaving the timing context unclear.